🔗 Share this article

Government ministers and leading parliamentarians have expressed alarm that the United Kingdom's negotiated accords with Washington are "lacking a solid foundation." This stems from revelations that a so-called "milestone" deal on pharmaceutical tariffs, which commits to zero tariffs in exchange for the NHS facing higher prices, lacks any formal legal text beyond vague headline terms outlined by government press releases.

A Deal Without Detail

The arrangement concerning medicines, hailed as a "significant" achievement, remains an "broad understanding" without formal ratification. It has been highlighted that the official announcements from the UK and US governments present the deal in markedly contrasting terms. The British version celebrates securing "duty-free access" as a unique achievement, while the American announcement dwells on the agreement for the NHS to pay 25% more for new medications.

"We face a genuine possibility that the UK government has made commitments to raise drug prices in return for only a verbal promise from President Trump," commented David Henig, a trade policy analyst. "We know he has a tendency for not honouring his word."

A Pattern of Unreliability

Concerns have been amplified by Washington's move to put on ice the high-value digital accord, which was previously heralded as "a huge leap forward" in the bilateral relationship. The US pointed to a lack of progress from the UK on lowering trade barriers as the reason for the pause.

In a separate development, concessions promised for British farmers as part of an May trade agreement have yet to be formally approved by the US, despite a imminent January deadline. "We have been informed that that the US has not finalized the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

In confidential discussions, ministers have expressed concerns that the government's US-UK accords are lacking substance. One minister described the series of agreements as "built on sand," while another characterized the situation as the "prevailing condition" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, chair of the health select committee, argued: "What is even more astonishing than the US approach is the UK government's naive belief that his administration is a reliable partner. The NHS is not a bargaining chip."

Official Reassurances and Concrete Outcomes

Officials have sought to reduce the risk of the US withdrawing from the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been advocating for the agreement, desiring stability on imports and pricing, making it of tangible value than the paused tech deal.

Officials acknowledge that unpredictability is part and parcel of dealing with the Trump administration. However, they contend that the UK has secured concrete outcomes for businesses, such as lower steel tariffs compared to other nations. "Securing 25% steel tariffs, which is better than the rate for the rest of the world, is a concrete advantage," one official said.

Nevertheless, delays have arisen in enacting the May tariff agreement. Promised access for British beef have yet to be finalized, and the pledge to "reduce steel tariffs to zero" has not been fulfilled, with tariffs staying at 25%.

As negotiations continue, the two sides have planned to recommence talks on the suspended digital agreement in January, following what were described as "very positive" meetings between UK and US officials in Washington.